Diacylglycerol Acyltransferase-1 (DGAT1) Inhibition Perturbs Postprandial Gut Hormone Release | Zendy

Hua Lin | Zendy; Dunlu Chen | Zendy; Zhu Shen | Zendy; Lei Zhu | Zendy; Xuesong Ouyang | Zendy; Aurawan Vongs | Zendy; Yanqing Kan | Zendy; John M. Levorse | Zendy; Edward J. Kowalik | Zendy; Daphne Szeto | Zendy; Xiaorui Yao | Zendy; Jianying Xiao | Zendy; Shirley Chen | Zendy; Jinqi Liu | Zendy; M. Garcia-Calvo | Zendy; Myung K. Shin | Zendy; Shirly Pinto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Diacylglycerol Acyltransferase-1 (DGAT1) Inhibition Perturbs Postprandial Gut Hormone Release

Author(s) -

Hua Lin,

Dunlu Chen,

Zhu Shen,

Lei Zhu,

Xuesong Ouyang,

Aurawan Vongs,

Yanqing Kan,

John M. Levorse,

Edward J. Kowalik,

Daphne Szeto,

Xiaorui Yao,

Jianying Xiao,

Shirley Chen,

Jinqi Liu,

M. Garcia-Calvo,

Myung K. Shin,

Shirly Pinto

Publication year - 2013

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0054480

Subject(s) - postprandial , glucagon like peptide 1 , endocrinology , diacylglycerol kinase , medicine , peptide yy , chemistry , hormone , biology , type 2 diabetes , biochemistry , enzyme , diabetes mellitus , neuropeptide , receptor , protein kinase c , neuropeptide y receptor

Diacylglycerol acyltransferase-1 (DGAT1) is a potential therapeutic target for treatment of obesity and related metabolic diseases. However, the degree of DGAT1 inhibition required for metabolic benefits is unclear. Here we show that partial DGAT1 deficiency in mice suppressed postprandial triglyceridemia, led to elevations in glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) only following meals with very high lipid content, and did not protect from diet-induced obesity. Maximal DGAT1 inhibition led to enhanced GLP-1 and PYY secretion following meals with physiologically relevant lipid content. Finally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further enhancements in active GLP-1 in mice and dogs. The current study suggests that targeting DGAT1 to enhance postprandial gut hormone secretion requires maximal inhibition, and suggests combination with DPP-4i as a potential strategy to develop DGAT1 inhibitors for treatment of metabolic diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research